Retatrutide 30mg Vial
Triple-Agonist GIP/GLP-1/Glucagon — 30mg Lyophilised Vial
£90.00
1
🇬🇧UK Based & Shipped
99%+ Purity Guaranteed
Discreet, Vacuum-Sealed
Encrypted Checkout
All products include a verification code for authenticity
The world's first triple-receptor agonist targeting GIP, GLP-1, and glucagon pathways simultaneously — representing a paradigm shift in metabolic peptide research.
- Triple receptor agonist — first peptide to target GIP, GLP-1 and Glucagon simultaneously
- Industry-leading research data — up to 28.7% body weight reduction in TRIUMPH Phase 3 trials
- Energy expenditure — glucagon receptor activation increases metabolic rate
- Appetite & satiety — dual incretin signalling researched for reduced food intake
- Glucose & lipid control — studied for improved metabolic markers across all 3 pathways
- Most advanced metabolic peptide in research — paradigm shift over single/dual agonists
For Research Purposes Only
This product is supplied strictly for research and laboratory use only. Not intended for human consumption. Not for medical use. Not intended to diagnose, treat, cure, or prevent any disease.